Notably, recent research showed that TLR7/8 agonist‐loaded nanoparticles could be potent drivers of TAM re‐education into the pro‐inflammatory phenotype[35] and of dendritic cell (DC) activation in the tumor and the tumor‐draining lymph nodes,[36, 37, 38] resulting in significant anti‐tumor immunity and therapeutic efficacy. This evidence concerns the gene TLR7 and neoplasm.